TuHURA Biosciences Inc

TuHURA Biosciences Inc operates with a high price-to-book ratio of 7.15, indicating that the market is valuing the company significantly above its book value. The company's liquidity position is weak, as evidenced by a current ratio of 0.78, which is below 1, suggesting that the company may struggle to meet its short-term obligations with its current assets. The company's cash and equivalents amount to $3.62 million, which is relatively small compared to its market capitalization of $149.65 million. The company's profitability is negative, with a return on equity of -1.44% and a return on assets of -1.10%, both of which are below the industry median for biotechnology firms. The company reported a net loss of $30.05 million and an operating loss of $31.98 million in the latest period, indicating that it is not yet generating positive returns for shareholders. TuHURA Biosciences Inc's revenue is not disclosed in the provided data, and the company does not report segment or geographic revenue breakdowns. As a result, it is not possible to assess the company's exposure to specific markets or product lines. The company's operations are concentrated in the biotechnology sector, and its financial performance is closely tied to the success of its drug development pipeline. The company's growth trajectory is uncertain, as it has not provided revenue history or outlook data. The absence of revenue data makes it difficult to assess the company's growth potential or its ability to scale operations. The company's capital expenditures are minimal, with a capex of -$76,080, suggesting that it is not investing heavily in new facilities or equipment. The company's risk profile is characterized by low liquidity and low dilution risk. The company has a debt-to-equity ratio of 0.01, indicating that it is not heavily leveraged. However, the company's negative operating cash flow of -$27.63 million and free cash flow of -$30.07 million suggest that it is not generating sufficient cash to fund operations or reduce debt. The company has no immediate filing-based liquidity or dilution flags, but its financial position remains precarious. There are no recent events or filings disclosed in the provided data that would indicate significant changes in the company's operations or financial position. The company's stock is currently trading at $2.35, and analyst price targets range from $7.00 to $10.00, with a mean of $8.40 and a median of $8.00. The mean recommendation is 2.00, indicating a "buy" rating, but there are no strong-buy recommendations.